Vaxart, Inc. (VXRT)

0.7454 -0.0171 (-2.24%) At close: 04:00PM EDT

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 109

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sean N. Tucker Ph.D.	Senior VP & Chief Scientific Officer	481.52k	N/A	1969
Dr. James F. Cummings M.D.	Chief Medical Officer	526.96k	N/A	1967
Mr. Steven Lo	President, CEO & Director	N/A	N/A	1967
Mr. Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1988
Dr. Raymond D. Stapleton Jr., Ph.D.	Chief Technology Officer	N/A	N/A	1971
Mr. Edward B. Berg	Senior VP & General Counsel	N/A	N/A	1965
Ms. Shaily Jaini Garg	Senior Vice President of Clinical Development & Project Management	N/A	N/A	N/A
Dr. Rajesh Kapoor Ph.D.	Senior Vice President of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.